eflornithine has been researched along with African Sleeping Sickness in 166 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 7.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "The traditional treatment of African sleeping sickness (trypanosomiasis) with central nervous system involvement is an organic arsenical compound, melarsoprol, which is associated with severe and even life-threatening side effects." | 5.27 | African sleeping sickness in the United States. Successful treatment with eflornithine. ( Azimi, PH; Cummins, SK; Petru, AM; Sjoerdsma, A, 1988) |
| " Patients aged 15 years or older with confirmed second-stage T b gambiense infection were randomly assigned by computer-generated randomisation sequence to receive intravenous eflornithine (400 mg/kg per day, every 6 h; n=144) for 14 days or intravenous eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral nifurtimox (15 mg/kg per day, every 8 h) for 10 days (NECT; n=143)." | 5.14 | Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. ( Arnold, U; Baudin, E; Buard, V; Ghabri, S; Ghorashian, S; Ilunga, M; Kande, V; Karunakara, U; Kasparian, S; Kazadi-Kyanza, S; Mutangala, W; Mutombo, W; Ngouama, D; Pohlig, G; Priotto, G; Schmid, C; Torreele, E, 2009) |
| "The symposium provided dramatic evidence of the value of the use of polyamine inhibition via alpha-difluoromethylornithine (DFMO, eflornithine) for advances in chemotherapy of Trypanosoma brucei gambiense sleeping sickness and Pneumocystis carinii pneumonia in acquired immune deficiency syndrome (AIDS) and also for further understanding the metabolic importance of the ubiquitous polyamines in these organisms." | 5.06 | Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. ( Bacchi, CJ; Barlow, JL; Bey, P; Clarkson, AB; McCann, PP; Schecter, PJ; Sjoerdsma, A; Walzer, PD, 1986) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 3.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| " The diagnosis of 'West African sleeping sickness' was made and the patient was treated with eflornithine." | 3.72 | [Clinical reasoning and decision making in practice. A depressive foreign woman with symptoms of malaise]. ( Hart, W; Kager, PA; Koopmans, RP; Schipper, HG; Slee, PH, 2004) |
| "DL-alpha-Difluoromethylornithine, a polyamine biosynthesis inhibitor, and bleomycin, a currently used antineoplastic agent, have each previously been shown to be curative for acute short-term infections of mice with Trypanosoma brucei brucei, an African trypanosome closely related to those that cause the human disease African sleeping sickness." | 3.66 | Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis. ( Bacchi, CJ; Clarkson, AB; McCann, PP; Mellow, GH; Nathan, HC; Sjoerdsma, A, 1983) |
| "DL-alpha-Difluoromethylornithine (DFMO), a specific enzyme-activated irreversible inhibitor of ornithine decarboxylase (ODC) was previously shown to cure mice infected with Trypanosoma brucei brucei, a parasite of game and cattle in Africa and Trypanosoma brucei rhodesiense, a human African Sleeping Sickness pathogen." | 3.66 | Further studies on difluoromethylornithine in African trypanosomes. ( Amole, BO; Bacchi, CJ; Clarkson, AB; Hutner, SH; McCann, PP; Nathan, HC; Seed, JR; Sjoerdsma, A, 1981) |
| "Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT)." | 3.30 | Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial. ( Akwaso Massa, F; Asuka Akongo Nguba, A; Betu Kumeso, VK; Camara, M; Catusse, J; Delhomme, S; Embana Mankiara, H; Fifi Nzeza Bambuwu, A; Ilunga Wa Kyhi, M; Kalonji, WM; Kaninda Badibabi, L; Kasongo Bonama, A; Kavunga Lukula, P; Kobo Muanza, V; Layba Camara, M; Mahenzi Mbembo, H; Makaya Mayawula, J; Mariero Philemon, P; Mokilifi Nganyonyi, R; Mulenge Nasandhel, E; Mutanda Kalonji, S; Mwamba Miaka, E; Ngolo Tete, D; Nusbaumer, M; Prêtre, A; Rembry, S; Scherrer, B; Schneitter, S; Strub-Wourgaft, N; Tarral, A; Valverde Mordt, O, 2023) |
| " Eflornithine stereoselective pharmacokinetics needs to be considered if an oral dosage regimen is to be explored further." | 2.80 | Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. ( Ashton, M; Björkman, S; Doua, F; Jansson-Löfmark, R; Na-Bangchang, K, 2015) |
| " Safety was further assessed based on treatment emergent adverse events (AEs) occurring during hospitalisation." | 2.77 | In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. ( Blesson, S; Blum, J; Ghabri, S; Ilunga, M; Kande, V; Kisala, M; Kuemmerle, A; Lumpungu, I; Mordt, OV; Mubwa, N; Mutanda, S; Mutombo, W; Nganzobo, P; Schmid, C; Tete, D, 2012) |
| "Cure after treatment for human African trypanosomiasis (HAT) is assessed by examination of the cerebrospinal fluid every 6 months, for a total period of 2 years." | 2.75 | A CATT negative result after treatment for human African trypanosomiasis is no indication for cure. ( Boelaert, M; Büscher, P; Lejon, V; Ngoyi, DM, 2010) |
| "Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a fatal disease." | 2.73 | Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. ( Arnold, U; Ghabri, S; Ghorashian, S; Karunakara, U; Kasparian, S; Ngouama, D; Priotto, G, 2007) |
| " This open trial shows that DFMO is as active as and possibly less toxic than melarsoprol." | 2.67 | Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. ( Ethier, L; Loko, L; Milord, F; Mpia, B; Pépin, J, 1992) |
| "Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite Trypanosoma brucei gambiense or T." | 2.52 | A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness"). ( Goeree, R; Sutherland, CS; Tediosi, F; Yukich, J, 2015) |
| "Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa and is fatal without treatment." | 2.49 | Chemotherapy for second-stage human African trypanosomiasis. ( Kennedy, A; Lutje, V; Seixas, J, 2013) |
| "Human African trypanosomiasis (HAT) has been neglected for a long time." | 2.49 | Drug discovery and human African trypanosomiasis: a disease less neglected? ( Baell, JB; Ferrins, L; Rahmani, R, 2013) |
| " The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage and treatment time for eflornithine that has significantly lessened the cost and improved the burden of logistics encountered during treatment and distribution." | 2.48 | Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. ( Diarra, A; Franco, J; Jannin, J; Postigo, JA; Simarro, PP, 2012) |
| "Human African trypanosomiasis or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei." | 2.47 | Drug resistance in human African trypanosomiasis. ( Barrett, MP; Burchmore, RJ; Kazibwe, AJ; Matovu, E; Vincent, IM, 2011) |
| "Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa and is fatal without treatment." | 2.46 | Chemotherapy for second-stage Human African trypanosomiasis. ( Kennedy, A; Lutje, V; Seixas, J, 2010) |
| " A combination chemotherapy, eflornithine alongside nifurtimox, has been introduced to decrease the time frame and overall dosing of eflornithine and reducing the risk of drug resistance emerging." | 2.46 | Potential new drugs for human African trypanosomiasis: some progress at last. ( Barrett, MP, 2010) |
| "The literature on MRI in human African trypanosomiasis is reviewed." | 2.45 | Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature. ( Kager, PA; Majoie, CB; Schipper, HG; Stam, J, 2009) |
| "Human African trypanosomiasis is a fatal disease caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense that has re-emerged in recent years." | 2.42 | Current chemotherapy of human African trypanosomiasis. ( Docampo, R; Moreno, SN, 2003) |
| " The most commonly used dosage regimen for the treatment of T." | 2.42 | Eflornithine for the treatment of human African trypanosomiasis. ( Brun, R; Burri, C, 2003) |
| "Human African trypanosomiasis re-emerged in the 1980s." | 2.41 | Treatment of human African trypanosomiasis--present situation and needs for research and development. ( Burri, C; Büscher, P; Gastellu-Etchegorry, M; Jannin, J; Legros, D; Ollivier, G; Paquet, C, 2002) |
| "Human African trypanosomiasis (sleeping sickness) caused by Trypanosoma gambiense is recrudescing alarmingly in the Ivory Coast." | 2.38 | Human trypanosomiasis in the Ivory Coast: therapy and problems. ( Doua, F; Yapo, FB, 1993) |
| "In animal models, treatment of African trypanosomiasis with difluoromethylornithine or melarsoprol requires an appropriate antibody-mediated immune response." | 2.38 | Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. ( Berger, BJ; Fairlamb, AH, 1992) |
| " Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine." | 1.72 | Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. ( Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022) |
| "Human African trypanosomiasis caused by Trypanosoma brucei gambiense is a parasitic infection that usually progresses to coma and death unless treated." | 1.56 | New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. ( Akl, EA; Barrett, MP; Bergman, H; Chappuis, F; Erphas, O; Franco, JR; Kadima Ebeja, A; Kazumba, L; Lejon, V; Lindner, AK; Mwamba, E; Priotto, G; Seixas, J; Simarro, P; Villanueva, G, 2020) |
| "Human African trypanosomiasis is endemic to parts of sub-Saharan Africa and should be considered in the differential diagnosis of patients who have visited or lived in Africa." | 1.48 | Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017. ( Chen, M; Gu, J; Liu, Q; Lu, Q; Qian, Y; Ruan, Q; Wang, X; Xu, B; Zhang, W, 2018) |
| "Human African trypanosomiasis (HAT), also referred to as "sleeping sickness", is caused by the parasite Trypanosoma brucei." | 1.40 | Human African trypanosomiasis with 7-year incubation period: clinical, laboratory and neuroimaging findings. ( Hegasy, G; Kopp, M; Siebert, E; Stenzel, W; Stich, A; Suttorp, N; Wengert, O; Zoller, T, 2014) |
| "Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei ." | 1.39 | Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. ( Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C, 2013) |
| "Eflornithine is used as a first line treatment for human African trypanosomiasis, but there is a risk that resistance could thwart its use, even when used in combination therapy with nifurtimox." | 1.36 | A molecular mechanism for eflornithine resistance in African trypanosomes. ( Barrett, MP; Burchmore, RJ; Creek, D; Kamleh, MA; Vincent, IM; Watson, DG; Wong, PE; Woods, DJ, 2010) |
| "Today, human African trypanosomiasis is an extremely rare diagnosis, especially in children." | 1.36 | [Human African trypanosomiasis: description of two pediatric cases in Yaoundé, Cameroon]. ( Akazong, CA; Boula, A; Chelo, D; Ebo'O Eyenga, V; Kinkela, MN; Kohagne Tongue, L; Kyebyene, A; Tietche, F, 2010) |
| "Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa." | 1.36 | Human African trypanosomiasis. ( Blum, J; Brun, R; Burri, C; Chappuis, F, 2010) |
| "During the first stage of human African trypanosomiasis (HAT), Trypanosoma brucei gambiense is found mainly in the blood, and pentamidine treatment is used." | 1.35 | Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. ( De Koning, HP; Dogruel, M; Rodgers, J; Sanderson, L; Thomas, SA, 2009) |
| "Drugs to treat African trypanosomiasis are toxic, expensive and subject to parasite resistance." | 1.35 | The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. ( Bradley, B; Dogruel, M; Rodgers, J; Sanderson, L; Thomas, SA, 2008) |
| "gambiense sleeping sickness (Human African Trypanosomiasis, HAT) patients treated with a combination of nifurtimox and eflornithine (N+E) in Yumbe, northwest Uganda in 2002-2003, following on a previously reported terminated trial in nearby Omugo, in which 17 patients received the combination under the same conditions." | 1.34 | Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. ( Ayikoru, H; Checchi, F; Legros, D; Piola, P; Priotto, G; Thomas, F, 2007) |
| "2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708)." | 1.33 | Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. ( Bovier, PA; Chappuis, F; Meussen, A; Stietenroth, K; Udayraj, N, 2005) |
| "Eflornithine seems to be a better first-line therapy for treating late-stage Gambian trypanosomiasis in the Republic of the Congo." | 1.33 | Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. ( Balasegaram, M; Checchi, F; Ghorashian, S; Hamel, C; Harris, S; Karunakara, U, 2006) |
| "Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance." | 1.31 | Availability and affordability of treatment for Human African Trypanosomiasis. ( Etchegorry, MG; Helenport, JP; Jannin, J; Legros, D; Pecoul, B, 2001) |
| "The treatment of late-stage human African trypanosomiasis is complicated by a post-treatment reactive encephalopathy, also referred to as a 'reactive arsenical encephalopathy', that may be fatal." | 1.30 | The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. ( Burke, JM; Gichuki, CW; Hunter, CA; Jennings, FW; Kennedy, PG; Murray, M; Rodgers, J, 1997) |
| " In this study, we propose a strategy to enhance the bioavailability of DFMO by using lipidomimetic derivatives." | 1.30 | Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model. ( Bourass, J; Chauffert, O; Czok, M; Letourneux, Y; Loiseau, PM, 1998) |
| "Treatment with melarsoprol in two cases and eflornithine in one case led to complete recovery." | 1.30 | [Sleeping sickness in children at Bobo-Dioulasso Hospital Center: apropos of 3 cases]. ( Bonkoungou, P; Millogo, A; Nacro, B; Sanou, M; Tall, F; Traoré, H; Traoré, S, 1999) |
| "Drug treatment of late-stage human African Trypanosomiasis (HAT) in which the central nervous system (CNS) is involved may be complicated by a severe post-treatment reactive encephalopathy (PTRE) which can be fatal in up to 10% of cases." | 1.30 | The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis. ( Kennedy, PG, 1999) |
| "Treatment with eflornithine (Ornidyl) resulted in complete recovery." | 1.29 | [Sleeping sickness as an import pathology following a stay in Zaire]. ( Buyse, D; Van den Ende, J; Van den Enden, E; Vervoort, T, 1996) |
| " Optimum dosage and duration of therapy, modes of administration and potential for large scale use are discussed." | 1.28 | Advances in sleeping sickness therapy. ( Van Nieuwenhove, S, 1992) |
| "Diminazene aceturate was more efficient and provided a 40 mg-kg dose was utilised, it was possible to reduce the period of DFMO to approximately 12 days." | 1.28 | Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). ( Jennings, FW, 1992) |
| " A (donor) mouse, infected for 28 days, is dosed with a drug, or combination of drugs, and samples of blood, cerebral cortex, choroid plexus and lining of ventricle are injected into clean (recipient) mice." | 1.27 | Screening compounds for sleeping sickness therapy without relapse. ( Ormerod, WE; Raseroka, BH, 1988) |
| " Both inhibitors cured the TREU 667 and LUMP 1001 isolates if used in combination with a single (20 mg/kg) injection of suramin, a trypanocide in current clinical use." | 1.27 | Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. ( Bacchi, CJ; Bienen, EJ; Bitonti, AJ; Clarkson, AB; McCann, PP; Nathan, HC; Sjoerdsma, A, 1987) |
| " Five patients are described with Gambian trypanosomiasis treated in Belgium with difluoromethylornithine, using various intravenous and oral dosage schedules." | 1.27 | Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients. ( Dasnoy, J; Haegele, KD; Kazyumba, G; Marcelis, L; Schechter, PJ; Sjoerdsma, A; Sonnet, J; Taelman, H; Wery, M, 1987) |
| "The traditional treatment of African sleeping sickness (trypanosomiasis) with central nervous system involvement is an organic arsenical compound, melarsoprol, which is associated with severe and even life-threatening side effects." | 1.27 | African sleeping sickness in the United States. Successful treatment with eflornithine. ( Azimi, PH; Cummins, SK; Petru, AM; Sjoerdsma, A, 1988) |
| "Human African trypanosomiasis (HAT) in Zaïre is a medical problem of first importance, particularly in endemic areas where sleeping sickness threatens about 10 millions of human beings almost the third of the whole population." | 1.27 | [Arsenical resistance and difluoromethylornithine in the treatment of human African trypanosomiasis]. ( Kazyumba, GL; Nkanga, N; Ruppol, JF; Tshefu, AK, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (24.70) | 18.7374 |
| 1990's | 37 (22.29) | 18.2507 |
| 2000's | 42 (25.30) | 29.6817 |
| 2010's | 39 (23.49) | 24.3611 |
| 2020's | 7 (4.22) | 2.80 |
| Authors | Studies |
|---|---|
| Sokolova, AY | 1 |
| Wyllie, S | 1 |
| Patterson, S | 1 |
| Oza, SL | 1 |
| Read, KD | 1 |
| Fairlamb, AH | 2 |
| Trunz, BB | 1 |
| Jędrysiak, R | 1 |
| Tweats, D | 1 |
| Brun, R | 5 |
| Kaiser, M | 2 |
| Suwiński, J | 1 |
| Torreele, E | 2 |
| Patel, G | 1 |
| Karver, CE | 1 |
| Behera, R | 1 |
| Guyett, PJ | 1 |
| Sullenberger, C | 1 |
| Edwards, P | 1 |
| Roncal, NE | 1 |
| Mensa-Wilmot, K | 1 |
| Pollastri, MP | 1 |
| Zimmermann, S | 1 |
| Oufir, M | 1 |
| Leroux, A | 1 |
| Krauth-Siegel, RL | 1 |
| Becker, K | 1 |
| Hamburger, M | 1 |
| Adams, M | 1 |
| Abdeen, S | 1 |
| Salim, N | 1 |
| Mammadova, N | 1 |
| Summers, CM | 1 |
| Goldsmith-Pestana, K | 1 |
| McMahon-Pratt, D | 1 |
| Schultz, PG | 1 |
| Horwich, AL | 1 |
| Chapman, E | 1 |
| Johnson, SM | 1 |
| Kuemmerle, A | 3 |
| Schmid, C | 6 |
| Bernhard, S | 1 |
| Kande, V | 4 |
| Mutombo, W | 4 |
| Ilunga, M | 4 |
| Lumpungu, I | 3 |
| Mutanda, S | 3 |
| Nganzobo, P | 3 |
| Tete, DN | 1 |
| Kisala, M | 3 |
| Burri, C | 5 |
| Blesson, S | 2 |
| Valverde Mordt, O | 5 |
| Amilon, C | 1 |
| Boberg, M | 1 |
| Tarning, J | 1 |
| Äbelö, A | 1 |
| Ashton, M | 2 |
| Jansson-Löfmark, R | 2 |
| Betu Kumeso, VK | 3 |
| Kalonji, WM | 3 |
| Rembry, S | 3 |
| Ngolo Tete, D | 3 |
| Prêtre, A | 3 |
| Delhomme, S | 3 |
| Ilunga Wa Kyhi, M | 3 |
| Camara, M | 3 |
| Catusse, J | 3 |
| Schneitter, S | 3 |
| Nusbaumer, M | 3 |
| Mwamba Miaka, E | 3 |
| Mahenzi Mbembo, H | 3 |
| Makaya Mayawula, J | 3 |
| Layba Camara, M | 3 |
| Akwaso Massa, F | 3 |
| Kaninda Badibabi, L | 3 |
| Kasongo Bonama, A | 3 |
| Kavunga Lukula, P | 3 |
| Mutanda Kalonji, S | 3 |
| Mariero Philemon, P | 3 |
| Mokilifi Nganyonyi, R | 3 |
| Embana Mankiara, H | 3 |
| Asuka Akongo Nguba, A | 3 |
| Kobo Muanza, V | 3 |
| Mulenge Nasandhel, E | 3 |
| Fifi Nzeza Bambuwu, A | 3 |
| Scherrer, B | 3 |
| Strub-Wourgaft, N | 3 |
| Tarral, A | 3 |
| Melfi, F | 1 |
| Carradori, S | 1 |
| Campestre, C | 1 |
| Haloci, E | 1 |
| Ammazzalorso, A | 1 |
| Grande, R | 1 |
| D'Agostino, I | 1 |
| Lindner, AK | 1 |
| Lejon, V | 2 |
| Chappuis, F | 7 |
| Seixas, J | 3 |
| Kazumba, L | 2 |
| Barrett, MP | 7 |
| Mwamba, E | 1 |
| Erphas, O | 1 |
| Akl, EA | 1 |
| Villanueva, G | 1 |
| Bergman, H | 1 |
| Simarro, P | 1 |
| Kadima Ebeja, A | 1 |
| Priotto, G | 7 |
| Franco, JR | 1 |
| Boukobza, M | 1 |
| Lariven, S | 1 |
| Houzé, S | 1 |
| Laissy, JP | 1 |
| Ngolo, D | 1 |
| Steverding, D | 2 |
| Rushworth, SA | 1 |
| Macedo, JP | 1 |
| Currier, RB | 1 |
| Wirdnam, C | 1 |
| Horn, D | 2 |
| Alsford, S | 2 |
| Rentsch, D | 1 |
| Gaillot, K | 1 |
| Lauvin, MA | 1 |
| Cottier, JP | 1 |
| Wang, X | 1 |
| Ruan, Q | 1 |
| Xu, B | 1 |
| Gu, J | 1 |
| Qian, Y | 1 |
| Chen, M | 1 |
| Liu, Q | 1 |
| Lu, Q | 1 |
| Zhang, W | 1 |
| Kansiime, F | 1 |
| Adibaku, S | 1 |
| Wamboga, C | 1 |
| Idi, F | 1 |
| Kato, CD | 1 |
| Yamuah, L | 1 |
| Vaillant, M | 1 |
| Kioy, D | 1 |
| Olliaro, P | 1 |
| Matovu, E | 4 |
| Kazumba, LM | 1 |
| Kaka, JT | 1 |
| Ngoyi, DM | 2 |
| Tshala-Katumbay, D | 1 |
| Kolosevska, K | 1 |
| Sánchez-Moreno, M | 1 |
| Dama, E | 1 |
| Drabo, A | 1 |
| Kaboré, J | 2 |
| Ouédraogo, E | 1 |
| Coulibaly, B | 1 |
| Ilboudo, H | 1 |
| Compaoré, CF | 1 |
| Sakandé, H | 1 |
| Ouédraogo, M | 1 |
| Rayaissé, JB | 1 |
| Courtin, F | 1 |
| Solano, P | 1 |
| Drabo, F | 1 |
| Jamonneau, V | 1 |
| Chen, N | 1 |
| Jin, K | 1 |
| Xu, J | 1 |
| Zhang, J | 1 |
| Weng, Y | 1 |
| Lutje, V | 2 |
| Kennedy, A | 2 |
| Stich, A | 3 |
| Ponte-Sucre, A | 1 |
| Holzgrabe, U | 1 |
| Ferrins, L | 1 |
| Rahmani, R | 1 |
| Baell, JB | 1 |
| Wengert, O | 1 |
| Kopp, M | 1 |
| Siebert, E | 1 |
| Stenzel, W | 1 |
| Hegasy, G | 1 |
| Suttorp, N | 1 |
| Zoller, T | 1 |
| Na-Bangchang, K | 2 |
| Björkman, S | 1 |
| Doua, F | 8 |
| Sutherland, CS | 1 |
| Yukich, J | 1 |
| Goeree, R | 1 |
| Tediosi, F | 1 |
| Hedley, L | 1 |
| Fink, D | 1 |
| Sparkes, D | 1 |
| Chiodini, PL | 1 |
| Dauchy, FA | 1 |
| Bonhivers, M | 1 |
| Landrein, N | 1 |
| Dacheux, D | 1 |
| Courtois, P | 1 |
| Lauruol, F | 1 |
| Daulouède, S | 1 |
| Vincendeau, P | 1 |
| Robinson, DR | 1 |
| Sanderson, L | 2 |
| Dogruel, M | 2 |
| Rodgers, J | 3 |
| Bradley, B | 1 |
| Thomas, SA | 2 |
| Balasegaram, M | 5 |
| Young, H | 1 |
| Raguenaud, ME | 2 |
| Checchi, F | 5 |
| De Koning, HP | 2 |
| Kager, PA | 3 |
| Schipper, HG | 2 |
| Stam, J | 1 |
| Majoie, CB | 1 |
| Kasparian, S | 2 |
| Ngouama, D | 2 |
| Ghorashian, S | 3 |
| Arnold, U | 2 |
| Ghabri, S | 3 |
| Baudin, E | 1 |
| Buard, V | 1 |
| Kazadi-Kyanza, S | 1 |
| Mutangala, W | 1 |
| Pohlig, G | 1 |
| Karunakara, U | 4 |
| Opigo, J | 1 |
| Woodrow, C | 1 |
| Blum, J | 2 |
| Schlitzer, M | 1 |
| Boelaert, M | 2 |
| Büscher, P | 2 |
| Kinkela, MN | 1 |
| Chelo, D | 1 |
| Boula, A | 1 |
| Ebo'O Eyenga, V | 1 |
| Kohagne Tongue, L | 1 |
| Akazong, CA | 1 |
| Kyebyene, A | 1 |
| Tietche, F | 1 |
| Cherian, P | 1 |
| Junckerstorff, RK | 1 |
| Rosen, D | 1 |
| Kumarasinghe, P | 1 |
| Morling, A | 1 |
| Tuch, P | 1 |
| Raven, S | 1 |
| Murray, RJ | 1 |
| Heath, CH | 1 |
| Yun, O | 1 |
| Tong, J | 1 |
| Flevaud, L | 1 |
| Vincent, IM | 2 |
| Creek, D | 1 |
| Watson, DG | 1 |
| Kamleh, MA | 1 |
| Woods, DJ | 1 |
| Wong, PE | 1 |
| Burchmore, RJ | 2 |
| Oba, A | 1 |
| Gahtse, A | 1 |
| Ekouya Bowassa, G | 1 |
| Nika, E | 1 |
| Kazibwe, AJ | 1 |
| Truc, P | 1 |
| Lando, A | 1 |
| Penchenier, L | 1 |
| Vatunga, G | 1 |
| Josenando, T | 2 |
| Eckert, S | 1 |
| Baker, N | 1 |
| Glover, L | 1 |
| Sanchez-Flores, A | 1 |
| Leung, KF | 1 |
| Turner, DJ | 1 |
| Field, MC | 1 |
| Berriman, M | 1 |
| Simarro, PP | 2 |
| Franco, J | 1 |
| Diarra, A | 1 |
| Postigo, JA | 1 |
| Jannin, J | 5 |
| Alirol, E | 1 |
| Schrumpf, D | 1 |
| Amici Heradi, J | 1 |
| Riedel, A | 1 |
| de Patoul, C | 1 |
| Quere, M | 1 |
| Tete, D | 1 |
| Mubwa, N | 1 |
| Mordt, OV | 1 |
| Gu, X | 1 |
| Reid, D | 1 |
| Higham, DJ | 1 |
| Gilbert, D | 1 |
| Legros, D | 4 |
| Ollivier, G | 1 |
| Gastellu-Etchegorry, M | 1 |
| Paquet, C | 1 |
| Stephan, C | 1 |
| Just-Nuebling, G | 1 |
| Fichtlscherer, S | 1 |
| Kriener, S | 1 |
| Brodt, HR | 1 |
| Wickware, P | 1 |
| Docampo, R | 1 |
| Moreno, SN | 1 |
| Abel, PM | 1 |
| Kiala, G | 1 |
| Lôa, V | 1 |
| Behrend, M | 1 |
| Musolf, J | 1 |
| Fleischmann, H | 1 |
| Théophile, J | 1 |
| Krishna, S | 1 |
| Rocha, G | 1 |
| Martins, A | 1 |
| Gama, G | 1 |
| Brandão, F | 1 |
| Atouguia, J | 1 |
| Louis, FJ | 1 |
| Keiser, J | 1 |
| Hart, W | 1 |
| Slee, PH | 1 |
| Koopmans, RP | 1 |
| Konsil, J | 1 |
| Hanpitakpong, W | 1 |
| Kamanikom, B | 1 |
| Kuzoe, F | 2 |
| Udayraj, N | 1 |
| Stietenroth, K | 1 |
| Meussen, A | 1 |
| Bovier, PA | 1 |
| Dejene, S | 1 |
| Tinnemann, P | 1 |
| Perkins, S | 1 |
| Davidson, R | 1 |
| Nishimura, K | 1 |
| Yanase, T | 1 |
| Araki, N | 1 |
| Ohnishi, Y | 1 |
| Kozaki, S | 1 |
| Shima, K | 1 |
| Asakura, M | 1 |
| Samosomsuk, W | 1 |
| Yamasaki, S | 1 |
| Harris, S | 2 |
| Hamel, C | 2 |
| Heby, O | 1 |
| Persson, L | 1 |
| Rentala, M | 1 |
| Taylor, MC | 1 |
| Kaur, H | 1 |
| Blessington, B | 1 |
| Kelly, JM | 1 |
| Wilkinson, SR | 1 |
| Piola, P | 1 |
| Ayikoru, H | 1 |
| Thomas, F | 1 |
| Blum, JA | 1 |
| Hatz, C | 1 |
| Mangoni, P | 1 |
| Zellweger, MJ | 1 |
| Robays, J | 1 |
| Pinoges, L | 1 |
| Fursa, IB | 1 |
| Burke, B | 1 |
| Nicolay, N | 1 |
| Grillet, G | 1 |
| Hewison, C | 1 |
| McCann, PP | 22 |
| Bacchi, CJ | 18 |
| Clarkson, AB | 8 |
| Seed, JR | 2 |
| Nathan, HC | 12 |
| Amole, BO | 1 |
| Hutner, SH | 7 |
| Sjoerdsma, A | 24 |
| Garofalo, J | 1 |
| Mockenhaupt, D | 1 |
| Diekema, KA | 1 |
| Pegg, AE | 2 |
| Mullaney, EA | 1 |
| Chunosoff, L | 1 |
| Mellow, GH | 1 |
| Hanson, WL | 1 |
| Schechter, PJ | 10 |
| de Gee, AL | 2 |
| Mansfield, JM | 2 |
| Bienen, EJ | 2 |
| Carstens, PH | 1 |
| Golden, JA | 1 |
| Barlow, JL | 2 |
| Santi, DV | 1 |
| Rescigno, D | 1 |
| Karbe, E | 1 |
| Böttger, M | 1 |
| Freitas, EK | 1 |
| Zola, JM | 1 |
| Wassoumbou-Loubienga, S | 1 |
| Goma, GC | 1 |
| Mouanga-Yidika, G | 1 |
| Boa Yapo, F | 1 |
| Yunmbam, MK | 1 |
| Roberts, JF | 1 |
| Burudi, EM | 1 |
| Karanja, SM | 1 |
| Njue, AI | 1 |
| Githiori, JB | 1 |
| Ndung'u, JM | 1 |
| Yapo, FB | 1 |
| Yarlett, N | 4 |
| Pépin, J | 4 |
| Milord, F | 3 |
| Kazumba, M | 1 |
| Kazadi, K | 1 |
| Mulumba, MP | 1 |
| Goldberg, B | 2 |
| Saric, M | 1 |
| Iten, M | 1 |
| Kaminsky, R | 3 |
| Buyse, D | 1 |
| Van den Ende, J | 1 |
| Vervoort, T | 1 |
| Van den Enden, E | 2 |
| Loiseau, PM | 2 |
| Chauffert, O | 2 |
| Czok, M | 2 |
| Jennings, FW | 5 |
| Gichuki, CW | 1 |
| Kennedy, PG | 2 |
| Hunter, CA | 1 |
| Murray, M | 1 |
| Burke, JM | 1 |
| Cattand, P | 1 |
| Youan, BB | 1 |
| Coulibaly, S | 1 |
| Miezan, TB | 1 |
| Bamba, M | 1 |
| Bourass, J | 1 |
| Letourneux, Y | 1 |
| Pécoul, B | 2 |
| Gastellu, M | 1 |
| Barrett, SV | 1 |
| Millogo, A | 1 |
| Nacro, B | 1 |
| Bonkoungou, P | 1 |
| Sanou, M | 1 |
| Traoré, S | 1 |
| Traoré, H | 1 |
| Tall, F | 1 |
| Bédat-Millet, AL | 1 |
| Charpentier, S | 1 |
| Monge-Strauss, MF | 1 |
| Woimant, F | 1 |
| Schull, M | 1 |
| Van Nieuwenhove, S | 3 |
| Khonde, N | 1 |
| Maiso, F | 1 |
| Jaffar, S | 1 |
| Ngampo, S | 1 |
| Mpia, B | 2 |
| Mbulamberi, D | 1 |
| Enyaru, JC | 1 |
| Seebeck, T | 1 |
| Coyne, PE | 1 |
| Etchegorry, MG | 1 |
| Helenport, JP | 1 |
| Hamon, JF | 2 |
| Camara, P | 2 |
| Berger, BJ | 1 |
| Blanchot, I | 1 |
| Dabadie, A | 1 |
| Tell, G | 1 |
| Guiguen, C | 1 |
| Faugère, B | 2 |
| Plat-Pelle, AM | 1 |
| Roussey, M | 1 |
| Loko, L | 1 |
| Ethier, L | 1 |
| Bitonti, AJ | 6 |
| Zweygarth, E | 1 |
| Onyeyili, PA | 3 |
| Egwu, GO | 1 |
| Zaria, LT | 1 |
| Orjiude, BA | 1 |
| Onwualu, JE | 1 |
| Byers, TL | 1 |
| Bush, TL | 1 |
| Casara, PJ | 1 |
| Aboagye-Kwarteng, T | 1 |
| ole-MoiYoi, OK | 1 |
| Lonsdale-Eccles, JD | 1 |
| Quamina, A | 1 |
| Seri, B | 1 |
| Aba, L | 1 |
| Anika, SM | 1 |
| Demey, F | 1 |
| Ormerod, WE | 1 |
| Raseroka, BH | 1 |
| Giffin, BF | 1 |
| Van Bogaert, I | 1 |
| Haemers, A | 1 |
| Bales, JD | 1 |
| Harrison, SM | 1 |
| Mbwabi, DL | 1 |
| Schecter, PJ | 2 |
| Benhamou, PH | 1 |
| Chandenier, J | 1 |
| Epelbaum, S | 1 |
| Tell, GP | 1 |
| Haegele, KD | 3 |
| Pautard, JC | 1 |
| Piussan, C | 1 |
| Guern, C | 1 |
| di Bari, C | 1 |
| Pastore, G | 1 |
| Roscigno, G | 1 |
| Bey, P | 1 |
| Walzer, PD | 1 |
| Taelman, H | 2 |
| Marcelis, L | 2 |
| Sonnet, J | 2 |
| Kazyumba, G | 2 |
| Dasnoy, J | 1 |
| Wery, M | 2 |
| Scalabrino, G | 1 |
| Berens, RL | 1 |
| Klein, RS | 1 |
| Elegbe, IA | 1 |
| Rao, KV | 1 |
| Marr, JJ | 1 |
| Boa, FY | 1 |
| Miézan, TW | 1 |
| Diai, D | 1 |
| Sanon, SR | 1 |
| De Raadt, P | 1 |
| Konian, K | 1 |
| Ulrich, P | 1 |
| Cerami, A | 1 |
| Petru, AM | 1 |
| Azimi, PH | 1 |
| Cummins, SK | 1 |
| Eyckmans, L | 1 |
| Sechelski, JB | 1 |
| Bouteille, B | 2 |
| Darde, ML | 1 |
| Pestre-Alexandre, M | 1 |
| Breton, JC | 1 |
| Sonan, T | 1 |
| Kazyumba, GL | 1 |
| Ruppol, JF | 1 |
| Tshefu, AK | 1 |
| Nkanga, N | 1 |
| Declercq, J | 1 |
| Boné, G | 1 |
| Burke, J | 1 |
| Bourgeade, A | 1 |
| Nosny, Y | 1 |
| Pene, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encepha[NCT00906880] | Phase 4 | 630 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase[NCT00146627] | Phase 3 | 280 participants (Anticipated) | Interventional | Completed | |||
| Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase[NCT00330148] | Phase 3 | 435 participants | Interventional | 2001-03-31 | Terminated | ||
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes[NCT05594563] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-03-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for eflornithine and African Sleeping Sickness
| Article | Year |
|---|---|
Emerging compounds and therapeutic strategies to treat infections from
Topics: Animals; Eflornithine; Humans; Patents as Topic; Trypanocidal Agents; Trypanosoma brucei brucei; Try | 2023 |
Chemotherapy for second-stage human African trypanosomiasis.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Humans; Melarsoprol; Nifurti | 2013 |
Drug discovery and human African trypanosomiasis: a disease less neglected?
Topics: Clinical Trials as Topic; Drug Evaluation, Preclinical; Eflornithine; Humans; Neglected Diseases; Sm | 2013 |
A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness").
Topics: Africa; Animals; Cost-Benefit Analysis; Eflornithine; Humans; Insect Vectors; Models, Theoretical; N | 2015 |
Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature.
Topics: Adult; Eflornithine; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Trypanocidal Age | 2009 |
[Agents for the treatment of African sleeping sickness. Those developed in the last century].
Topics: Animals; Eflornithine; History, 20th Century; Humans; Melarsoprol; Nifurtimox; Pentamidine; Suramin; | 2009 |
NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness.
Topics: Africa South of the Sahara; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Endemic D | 2010 |
Chemotherapy for second-stage Human African trypanosomiasis.
Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Humans; Melarsoprol; Nifurti | 2010 |
Potential new drugs for human African trypanosomiasis: some progress at last.
Topics: Animals; Benzamides; Boron Compounds; Drug Discovery; Drug Resistance; Drug Therapy, Combination; Ef | 2010 |
Drug resistance in human African trypanosomiasis.
Topics: Animals; Drug Resistance; Eflornithine; Humans; Membrane Transport Proteins; Nifurtimox; Pentamidine | 2011 |
Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
Topics: Animals; Drug Therapy, Combination; Eflornithine; Health Services Accessibility; Humans; Melarsoprol | 2012 |
Treatment of human African trypanosomiasis--present situation and needs for research and development.
Topics: Africa South of the Sahara; Animals; Benzamidines; Drug Therapy, Combination; Eflornithine; Humans; | 2002 |
Current chemotherapy of human African trypanosomiasis.
Topics: Animals; Eflornithine; Humans; Melarsoprol; Pentamidine; Suramin; Trypanocidal Agents; Trypanosoma; | 2003 |
Eflornithine for the treatment of human African trypanosomiasis.
Topics: Animals; Eflornithine; Humans; Trypanocidal Agents; Trypanosoma brucei gambiense; Trypanosoma brucei | 2003 |
[Eflornithine in the treatment of African trypanosomiasis].
Topics: Eflornithine; Humans; Trypanocidal Agents; Trypanosomiasis, African | 2003 |
Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis.
Topics: Adenosine; Adenosylmethionine Decarboxylase; Animals; Biogenic Polyamines; Chagas Disease; Eflornith | 2007 |
Chemotherapeutic implications of polyamine biosynthesis inhibition.
Topics: Animals; Drug Evaluation; Eflornithine; Female; Humans; Male; Melanoma; Mice; Middle Aged; Ornithine | 1984 |
Human trypanosomiasis in the Ivory Coast: therapy and problems.
Topics: Animals; Cote d'Ivoire; Eflornithine; Humans; Melarsoprol; Pentamidine; Recurrence; Trypanosoma bruc | 1993 |
Effects of antagonists of polyamine metabolism on African trypanosomes.
Topics: Adenosylmethionine Decarboxylase; Animals; Deoxyadenosines; Eflornithine; Methylation; Polyamines; S | 1993 |
The treatment of human African trypanosomiasis.
Topics: Animals; Diminazene; Eflornithine; Humans; Melarsoprol; Nifurtimox; Pentamidine; Suramin; Trypanocid | 1994 |
Transporters in African trypanosomes: role in drug action and resistance.
Topics: Africa South of the Sahara; Animals; Arsenicals; Biological Transport; Eflornithine; Humans; Nitroim | 2001 |
Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases.
Topics: Animals; Antibody Formation; Antiprotozoal Agents; Eflornithine; Humans; Immunity, Cellular; Immunoc | 1992 |
Ornithine decarboxylase as an enzyme target for therapy.
Topics: Amino Acid Sequence; Animals; Autoimmune Diseases; Eflornithine; Humans; Molecular Sequence Data; Ne | 1992 |
Eflornithine. A new drug in the treatment of sleeping sickness.
Topics: Animals; Chagas Disease; Eflornithine; Humans; Trypanocidal Agents; Trypanosoma brucei gambiense; Tr | 1989 |
[DFMO: an alternative therapeutic agent for human African trypanosomiasis].
Topics: Animals; Eflornithine; Trypanosoma brucei brucei; Trypanosomiasis, African | 1988 |
15 trials available for eflornithine and African Sleeping Sickness
| Article | Year |
|---|---|
Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Topics: Adolescent; Adult; Aged; Antiprotozoal Agents; Child; Child, Preschool; Democratic Republic of the C | 2021 |
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Female; H | 2023 |
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Female; H | 2023 |
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Female; H | 2023 |
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Female; H | 2023 |
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo.
Topics: Democratic Republic of the Congo; Drug Therapy, Combination; Eflornithine; Humans; Nifurtimox; Treat | 2020 |
A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
Topics: Adolescent; Adult; Drug Therapy, Combination; Eflornithine; Female; Follow-Up Studies; Humans; Male; | 2018 |
Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Topics: Administration, Oral; Adolescent; Adult; Eflornithine; Female; Humans; Male; Middle Aged; Stereoisom | 2015 |
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Topics: Administration, Oral; Adult; Animals; Congo; Democratic Republic of the Congo; Drug Administration S | 2009 |
A CATT negative result after treatment for human African trypanosomiasis is no indication for cure.
Topics: Agglutination Tests; Antibodies, Protozoan; Eflornithine; Humans; Melarsoprol; Pentamidine; Treatmen | 2010 |
In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Topics: Adolescent; Adult; Child; Child, Preschool; Democratic Republic of the Congo; Drug Therapy, Combinat | 2012 |
The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.
Topics: Adolescent; Adult; Aged; Animals; Area Under Curve; Dose-Response Relationship, Drug; Eflornithine; | 2004 |
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Topics: Adolescent; Adult; Aged; Animals; Congo; Drug Therapy, Combination; Eflornithine; Female; Humans; Ma | 2007 |
Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis).
Topics: Adult; Animals; Eflornithine; Electrocardiography; Female; Heart Diseases; Humans; Male; Melarsoprol | 2007 |
Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial.
Topics: Adolescent; Adult; Africa, Central; Aged; Child; Child, Preschool; Drug Administration Schedule; Efl | 2000 |
Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
Topics: Administration, Oral; Animals; Cerebrospinal Fluid; Democratic Republic of the Congo; Diarrhea; Eflo | 1992 |
Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.
Topics: Acquired Immunodeficiency Syndrome; Animals; Clinical Trials as Topic; Eflornithine; Humans; Pneumoc | 1986 |
Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.
Topics: Adolescent; Adult; Cerebrospinal Fluid Proteins; Child; Clinical Trials as Topic; Eflornithine; Fema | 1985 |
126 other studies available for eflornithine and African Sleeping Sickness
| Article | Year |
|---|---|
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
Topics: Animals; Cell Line; Drug Resistance; Eflornithine; Humans; Mice; Nifurtimox; Trypanocidal Agents; Tr | 2010 |
1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
Topics: Animals; Antiprotozoal Agents; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Dr | 2011 |
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; | 2013 |
Cynaropicrin targets the trypanothione redox system in Trypanosoma brucei.
Topics: Amide Synthases; Enzyme Activation; Humans; Lactones; NADH, NADPH Oxidoreductases; Ornithine Decarbo | 2013 |
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
Topics: Animals; Antiprotozoal Agents; Chaperonin 10; Chaperonin 60; Drug Evaluation, Preclinical; High-Thro | 2016 |
Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Topics: Animals; Drug Therapy, Combination; Eflornithine; Humans; Nifurtimox; Trypanocidal Agents; Trypanoso | 2022 |
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiprotozoal Agents; Child; Child, Preschool; Eflornith | 2020 |
Unusual MRI Findings in African
Topics: Cerebellar Nuclei; Drug Therapy, Combination; Eflornithine; Humans; Hypothalamus; Magnetic Resonance | 2020 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Ornithine uptake and the modulation of drug sensitivity in
Topics: Animals; Antineoplastic Agents; Eflornithine; Humans; Ornithine; Ornithine Decarboxylase; Polyamines | 2017 |
Vertical transmission of human African trypanosomiasis: Clinical evolution and brain MRI of a mother and her son.
Topics: Brain; Eflornithine; Female; Humans; Infant; Infectious Disease Transmission, Vertical; Magnetic Res | 2017 |
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017.
Topics: China; Drug Therapy, Combination; Eflornithine; Emigrants and Immigrants; Gabon; Humans; Nifurtimox; | 2018 |
Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
Topics: Adolescent; Adult; Democratic Republic of the Congo; Disease Management; Drug Therapy, Combination; | 2018 |
Trypanocidal activity of tetradentated pyridine-based manganese complexes is not linked to inactivation of superoxide dismutase.
Topics: Antioxidants; Drug Interactions; Eflornithine; HL-60 Cells; Humans; Manganese Compounds; Microbial S | 2018 |
Description of the first sleeping sickness case diagnosed in Burkina Faso since two decades.
Topics: Adolescent; Burkina Faso; Eflornithine; Humans; Male; Trypanocidal Agents; Trypanosomiasis, African | 2018 |
Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China.
Topics: Animals; China; Communicable Diseases, Imported; Eflornithine; Fatal Outcome; Gabon; Humans; Male; M | 2019 |
Do we need new drugs against human African trypanosomiasis?
Topics: Animals; Clinical Trials as Topic; Disease Outbreaks; Drug Evaluation, Preclinical; Eflornithine; Hu | 2013 |
Human African trypanosomiasis with 7-year incubation period: clinical, laboratory and neuroimaging findings.
Topics: Adult; Anti-Inflammatory Agents; Cameroon; Eflornithine; Germany; Humans; Male; Neuroimaging; Treatm | 2014 |
African sleeping sickness.
Topics: Animals; Eflornithine; Humans; Insect Vectors; Nifurtimox; Pentamidine; Suramin; Trypanocidal Agents | 2016 |
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
Topics: 14-alpha Demethylase Inhibitors; Animals; Anti-Bacterial Agents; Cytokinesis; Disease Models, Animal | 2016 |
The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Carbon | 2008 |
Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angola; Animals; Child; Developing Countries; Eflornithi | 2009 |
Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein.
Topics: Adenine; Adenosine; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Bl | 2009 |
NECT trial: more than a small victory over sleeping sickness.
Topics: Animals; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Eflornithine; Humans; Multi | 2009 |
Human African trypanosomiasis.
Topics: Africa; Animals; Biomedical Research; Communicable Disease Control; Eflornithine; Endemic Diseases; | 2010 |
Killer coma: the evolving story of sleeping sickness treatment.
Topics: Animals; Biomedical Research; Drug Discovery; Drug Resistance; Drug Therapy, Combination; Eflornithi | 2010 |
[Human African trypanosomiasis: description of two pediatric cases in Yaoundé, Cameroon].
Topics: Cameroon; Child; Child, Preschool; Eflornithine; Fever; Humans; Male; Trypanocidal Agents; Trypanoso | 2010 |
Late-stage human African trypanosomiasis in a Sudanese refugee.
Topics: Australia; Cerebrospinal Fluid; Eflornithine; Female; Humans; Refugees; Sudan; Trypanocidal Agents; | 2010 |
A molecular mechanism for eflornithine resistance in African trypanosomes.
Topics: Amino Acid Transport Systems; Animals; Blotting, Southern; Drug Resistance; Eflornithine; Humans; Mi | 2010 |
[Congenital human African trypanosomiasis: an observation at the University Hospital of Brazzaville (Congo)].
Topics: Animals; Congo; Eflornithine; Fatal Outcome; Female; Hospitals, University; Humans; Infant, Newborn; | 2011 |
Human African trypanosomiasis in Angola: clinical observations, treatment, and use of PCR for stage determination of early stage of the disease.
Topics: Adult; Angola; Animals; Eflornithine; Female; Follow-Up Studies; Humans; Lymphocyte Count; Male; Nuc | 2012 |
High-throughput decoding of antitrypanosomal drug efficacy and resistance.
Topics: Aquaglyceroporins; Drug Resistance; Eflornithine; Endocytosis; Glycosylation; High-Throughput Screen | 2012 |
Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Child; Child, Preschool; Cohort Studies; Democratic Republic of the Congo; Drug T | 2013 |
Mathematical modelling of polyamine metabolism in bloodstream-form Trypanosoma brucei: an application to drug target identification.
Topics: Adenosylmethionine Decarboxylase; Animals; Computer Simulation; Eflornithine; Humans; Kinetics; Meta | 2013 |
Winterbottom's sign and hypertrophic cardiomyopathy.
Topics: Adult; Animals; Cardiomyopathy, Hypertrophic; Diagnosis, Differential; Eflornithine; Humans; Lymphat | 2002 |
Resurrecting the resurrection drug.
Topics: Africa; Antineoplastic Agents; Developing Countries; Drug Industry; Eflornithine; Humans; Life Style | 2002 |
[The return of sleeping sickness in an epidemic form: international action for drugs].
Topics: Africa, Central; Animals; Disease Outbreaks; Eflornithine; Humans; International Cooperation; Melars | 2002 |
Retaking sleeping sickness control in Angola.
Topics: Adolescent; Adult; Age Distribution; Aged; Angola; Animals; Child; Child, Preschool; Disease Outbrea | 2004 |
Possible cases of sexual and congenital transmission of sleeping sickness.
Topics: Adult; Animals; Carrier State; Eflornithine; Female; Humans; Infant; Male; Sexually Transmitted Dise | 2004 |
[Clinical reasoning and decision making in practice. A depressive foreign woman with symptoms of malaise].
Topics: Adult; Anemia; Angola; Animals; Blood Protein Electrophoresis; Brain; Depression; Eflornithine; Fati | 2004 |
Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Topics: Adolescent; Adult; Child; Eflornithine; Female; Humans; Male; Melarsoprol; Sudan; Trypanocidal Agent | 2005 |
Examples of tropical disease control in the humanitarian medical programmes of MSF and Merlin.
Topics: Antimalarials; Artemether; Artemisinins; Attitude to Health; Child; Child, Preschool; Communicable D | 2006 |
The rise and fall of sleeping sickness.
Topics: Africa; Animals; Drug Industry; Eflornithine; Humans; Trypanocidal Agents; Trypanosoma brucei gambie | 2006 |
Effects of polyamines on two strains of Trypanosoma brucei in infected rats and in vitro culture.
Topics: Amide Synthases; Animals; Culture Media; Eflornithine; Enzyme Inhibitors; Gene Expression Regulation | 2006 |
Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Topics: Adolescent; Adult; Animals; Child; Cohort Studies; Democratic Republic of the Congo; Disease Progres | 2006 |
Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Topics: Adolescent; Adult; Animals; Child; Democratic Republic of the Congo; Disease Progression; Eflornithi | 2006 |
Validation of spermidine synthase as a drug target in African trypanosomes.
Topics: Amino Acid Sequence; Animals; Eflornithine; Models, Biological; Molecular Sequence Data; Recombinant | 2008 |
Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.
Topics: Drug Resistance; Drug Therapy, Combination; Eflornithine; Gambia; Humans; Melarsoprol; Nifurtimox; T | 2007 |
Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series.
Topics: Adolescent; Adult; Child; Child, Preschool; Eflornithine; Female; Humans; Male; Middle Aged; Nifurti | 2007 |
Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.
Topics: Angola; Animals; Cost of Illness; Cost-Benefit Analysis; Eflornithine; Humans; Melarsoprol; Treatmen | 2008 |
African sleeping sickness.
Topics: Drug Resistance; Eflornithine; Humans; Trypanocidal Agents; Trypanosomiasis, African | 2008 |
Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study.
Topics: Adult; Child; Cohort Studies; Eflornithine; Female; Humans; Male; Risk Factors; Sudan; Treatment Out | 2008 |
Further studies on difluoromethylornithine in African trypanosomes.
Topics: Acute Disease; Animals; Arvicolinae; Bleomycin; Carboxy-Lyases; Central Nervous System Diseases; Chr | 1981 |
Novel combination chemotherapy of experimental trypanosomiasis by using bleomycin and DL-alpha-difluoromethylornithine; reversal by polyamines.
Topics: Animals; Bleomycin; Drug Therapy, Combination; Eflornithine; Mice; Ornithine; Polyamines; Time Facto | 1982 |
In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei.
Topics: Animals; DNA; Eflornithine; Female; Kinetics; Macromolecular Substances; Ornithine; Polyamines; Prot | 1983 |
Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis.
Topics: Animals; Bleomycin; Central Nervous System Diseases; Disease Models, Animal; Drug Therapy, Combinati | 1983 |
Methods for the study of the treatment of protozoan diseases by inhibitors of ornithine decarboxylase.
Topics: Animals; Chickens; Coccidiosis; Eflornithine; Female; Male; Mice; Ornithine; Ornithine Decarboxylase | 1983 |
Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy.
Topics: Animals; Antibodies; Antibody Formation; Antigens, Surface; Cyclophosphamide; Eflornithine; Immunosu | 1983 |
New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Eflornithine; Humans; Injections, Intrav | 1984 |
Morphological changes in Trypanosoma brucei rhodesiense following inhibition of polyamine biosynthesis in vivo.
Topics: Animals; Eflornithine; Erythrocytes; Mice; Mice, Inbred Strains; Microscopy, Electron; Ornithine; Or | 1984 |
Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Child; Eflornithine; Female; Humans; Male; Mi | 1984 |
Polyamine metabolism: a potential therapeutic target in trypanosomes.
Topics: Animals; Eflornithine; Mice; Ornithine; Ornithine Decarboxylase Inhibitors; Polyamines; Trypanocidal | 1980 |
Antagonism by polyamines of the curative effects of alpha-difluoromethylornithine in Trypanosoma brucei brucei infections.
Topics: Animals; Eflornithine; Female; Male; Mice; Ornithine; Polyamines; Trypanocidal Agents; Trypanosoma b | 1981 |
Curative effect of alpha-difluoromethylornithine on fatal Trypanosoma congolense infection in mice.
Topics: Animals; Dose-Response Relationship, Drug; Eflornithine; Female; Muridae; Ornithine; Trypanocidal Ag | 1982 |
[Acute Trypanosoma brucei gambiense meningoencephalitis detected by papillary edema].
Topics: Adult; Animals; Congo; Cosyntropin; Delta Rhythm; Eflornithine; Electroencephalography; Female; Huma | 1994 |
[Current therapy of trypanosomiasis].
Topics: Adenosylmethionine Decarboxylase; Animals; Arsenicals; Deoxyadenosines; Drug Resistance; Eflornithin | 1994 |
In vivo evaluation of reuterin and its combinations with suramin, melarsoprol, DL-alpha-difluoromethylornithine and bleomycin in mice infected with Trypanosoma brucei brucei.
Topics: Aldehydes; Animals; Anti-Bacterial Agents; Bleomycin; Drug Therapy, Combination; Eflornithine; Femal | 1993 |
Establishment of a partly DFMO-sensitive primate model of Trypanosoma rhodesiense sleeping sickness.
Topics: Animals; Chlorocebus aethiops; Disease Models, Animal; Drug Therapy, Combination; Eflornithine; Sura | 1995 |
[Characteristics of trypanosomiasis in children. Apropos of 19 case reports at the CNPP (Neuro-Psycho-Pathology Center), University Hospitals of Kinshasa, Zaire].
Topics: Adolescent; Child; Child, Preschool; Democratic Republic of the Congo; Drug Therapy, Combination; Ef | 1993 |
Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides.
Topics: Animals; Arsenicals; Diminazene; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Eflo | 1994 |
Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO).
Topics: Animals; Drug Resistance; Eflornithine; Female; Humans; Hypoxanthine; Hypoxanthines; Melarsoprol; Mi | 1995 |
[Sleeping sickness as an import pathology following a stay in Zaire].
Topics: Adult; Animals; Democratic Republic of the Congo; Eflornithine; Humans; Male; Travel; Trypanocidal A | 1996 |
Effect of chronic trypanosomiasis on the bioavailability of alpha-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Eflornithine; Female; Mice; | 1997 |
The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis.
Topics: Animals; Brain; Brain Diseases; Diminazene; Eflornithine; Female; Mice; Mice, Inbred Strains; Polyam | 1997 |
[Correspondence of the World Health Organization relative to the editorial by T. Ancelle (Med. Trop. 1996; 56: 347-348)].
Topics: Africa; Eflornithine; France; Global Health; Humans; International Cooperation; Melarsoprol; Pentami | 1997 |
In vivo evaluation of sixteen plant extracts on mice inoculated with Trypanosoma brucei gambiense.
Topics: Administration, Oral; Animals; Cote d'Ivoire; Eflornithine; Infusions, Parenteral; Injections, Intra | 1997 |
Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model.
Topics: Administration, Oral; Animals; Biological Availability; Culture Media; Disease Models, Animal; Drug | 1998 |
Eflornithine for African sleeping sickness.
Topics: Animals; Drug Approval; Drug Industry; Eflornithine; Humans; Trypanocidal Agents; Trypanosoma brucei | 1999 |
Production of sleeping-sickness treatment.
Topics: Cost-Benefit Analysis; Drug Compounding; Eflornithine; Humans; Melarsoprol; Sudan; Trypanocidal Agen | 1999 |
Anti-sleeping sickness drugs and cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Eflornithine; Humans; Melarsoprol; Pentamidine; Suramin; Trypanocida | 2000 |
[Sleeping sickness in children at Bobo-Dioulasso Hospital Center: apropos of 3 cases].
Topics: Adolescent; Burkina Faso; Child, Preschool; Cote d'Ivoire; Eflornithine; Female; Humans; Male; Melar | 1999 |
The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis.
Topics: Analgesics; Animals; Azathioprine; Disease Models, Animal; Eflornithine; Encephalitis; Hippocampus; | 1999 |
[Psychiatric presentation of human African trypanosomiasis: overview of diagnostic pitfalls, interest of difluoromethylornithine treatment and contribution of magnetic resonance imaging].
Topics: Adult; Animals; Brain; Diagnosis, Differential; Eflornithine; Humans; Magnetic Resonance Imaging; Ma | 2000 |
Lack of new drugs for tropical disease should not be accepted.
Topics: Drug Industry; Eflornithine; Humans; Trypanocidal Agents; Trypanosomiasis, African | 2000 |
Gambiense sleeping sickness: re-emerging and soon untreatable?
Topics: Africa, Central; Eflornithine; Humans; Trypanocidal Agents; Trypanosomiasis, African | 2000 |
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Topics: Animals; DNA, Protozoan; Drug Resistance; Eflornithine; Humans; Melarsoprol; Microbial Sensitivity T | 2001 |
The eflornithine story.
Topics: Administration, Topical; Developing Countries; Drug Industry; Eflornithine; Enzyme Inhibitors; Hirsu | 2001 |
Availability and affordability of treatment for Human African Trypanosomiasis.
Topics: Eflornithine; Health Services Accessibility; Humans; Melarsoprol; Pentamidine; Research; Suramin; Tr | 2001 |
[Electroencephalographic study of trypanosomes in meningoencephalitic stage of human African trypanosomiasis from Trypanosoma brucei gambiense before and after treatment with DL-alphadifluoromethyl- ornithine hydrochloride monohydrate (DFMO)].
Topics: Adolescent; Adult; Animals; Child; Eflornithine; Electroencephalography; Female; Humans; Male; Middl | 1992 |
[Recurrent fever episodes in an African child: diagnostic difficulties of trypanosomiasis in France].
Topics: Angola; Child, Preschool; Eflornithine; Fever; France; Humans; Male; Recurrence; Trypanosomiasis, Af | 1992 |
Advances in sleeping sickness therapy.
Topics: Animals; Clinical Trials as Topic; Democratic Republic of the Congo; Eflornithine; Humans; Melarsopr | 1992 |
Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor.
Topics: Adenosylmethionine Decarboxylase; Administration, Oral; Animals; Antiprotozoal Agents; Central Nervo | 1992 |
Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO).
Topics: Animals; Arsenicals; Central Nervous System Diseases; Diminazene; Drug Administration Schedule; Drug | 1992 |
Chemotherapy of trypanosomiasis: the potentiation of antimonial compounds by difluoromethylornithine (DFMO).
Topics: Animals; Antimony; Antimony Sodium Gluconate; Drug Synergism; Drug Therapy, Combination; Eflornithin | 1991 |
Evaluation of DL-alpha-difluoromethylornithine against susceptible and drug-resistant Trypanosoma brucei brucei.
Topics: Animals; Arsenicals; Culture Media; Diminazene; Drug Antagonism; Drug Synergism; Drug Therapy, Combi | 1991 |
DL-alpha-difluoromethylornithine (DFMO)-Berenil combination: therapeutic and prophylactic activity against Trypanosoma brucei brucei infection in mice.
Topics: Animals; Diminazene; Drug Therapy, Combination; Eflornithine; Mice; Trypanocidal Agents; Trypanosoma | 1991 |
Efficacy of combination of DFMO and diminazene aceturate in the treatment of late stage Trypanosoma brucei brucei infection in rats.
Topics: Animals; Brain Diseases; Diminazene; Drug Synergism; Drug Therapy, Combination; Eflornithine; Female | 1991 |
Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S-adenosylmethionine decarboxylase.
Topics: Adenosylmethionine Decarboxylase; Animals; Biogenic Polyamines; Deoxyadenosines; Drug Resistance, Mi | 1990 |
Phosphorylation differences among proteins of bloodstream developmental stages of Trypanosoma brucei brucei.
Topics: Animals; Eflornithine; Electrophoresis, Gel, Two-Dimensional; Magnesium; Manganese; Molecular Weight | 1991 |
Protein methylases in Trypanosoma brucei brucei: activities and response to DL-alpha-difluoromethylornithine.
Topics: Adenosine; Animals; Binding Sites; Binding, Competitive; Eflornithine; Histone-Lysine N-Methyltransf | 1991 |
Effects of Mel B arsobal and alpha-difluoromethylornithine on the awakening electroencephalogram of humans with gambiense trypanosomiasis disease: preliminary report.
Topics: Adolescent; Adult; Arsenicals; Dimercaprol; Drug Combinations; Eflornithine; Electroencephalography; | 1990 |
Effects of the combination of DL-alpha-difluoromethylornithine and diminazene aceturate in Trypanosoma congolense infection of dogs.
Topics: Animals; Diminazene; Dog Diseases; Dogs; Drug Therapy, Combination; Eflornithine; Female; Male; Tryp | 1990 |
Studies on the efficacy of DL-alpha-difluoromethylornithine (DFMO) associated with bleomycin and suramin for treatment of mice infected with metacyclic forms of Trypanosoma brucei brucei.
Topics: Animals; Bleomycin; Drug Therapy, Combination; Eflornithine; Female; Mice; Suramin; Trypanosoma bruc | 1987 |
Screening compounds for sleeping sickness therapy without relapse.
Topics: Animals; Bleomycin; Drug Evaluation, Preclinical; Eflornithine; Melarsoprol; Metronidazole; Mice; Su | 1988 |
Physiological activation of the mitochondrion and the transformation capacity of DFMO induced intermediate and short stumpy bloodstream form trypanosomes.
Topics: Animals; Dihydrolipoamide Dehydrogenase; Eflornithine; Histocytochemistry; Male; Microscopy, Electro | 1989 |
Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya.
Topics: Adult; Animals; Arsenicals; Drug Therapy, Combination; Eflornithine; Female; Humans; Kenya; Male; Me | 1989 |
[African trypanosomiasis in children treated with eflornithine. A case].
Topics: Adolescent; Animals; Asthenia; Eflornithine; Female; Headache; Humans; Sleep Wake Disorders; Trypano | 1989 |
The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis.
Topics: Animals; Antimony Sodium Gluconate; Arsenicals; Drug Synergism; Drug Therapy, Combination; Eflornith | 1988 |
Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
Topics: Administration, Oral; Adolescent; Animals; Arsenicals; Child; Child, Preschool; Diarrhea; Drug Resis | 1987 |
Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine.
Topics: Animals; Antibody Formation; Antigens, Protozoan; Dexamethasone; Eflornithine; Immunity; Immunosuppr | 1986 |
Late-stage African trypanosomiasis and eflornithine.
Topics: Adult; Eflornithine; Humans; Male; Trypanosoma brucei gambiense; Trypanosomiasis, African | 1986 |
Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.
Topics: Animals; Central Nervous System; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eflorn | 1987 |
Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis. Results in five patients.
Topics: Adult; Drug Administration Schedule; Eflornithine; Female; Humans; Kinetics; Male; Middle Aged; Tryp | 1987 |
Difluoromethylornithine, an effective new treatment of Gambian trypanosomiasis.
Topics: Animals; Drug Evaluation; Eflornithine; Helsinki Declaration; Humans; Trypanosoma brucei gambiense; | 1987 |
Synergism between 9-deazainosine and DL-alpha-difluoromethylornithine in treatment of experimental African trypanosomiasis.
Topics: Animals; Antimetabolites; Biotransformation; Drug Synergism; Eflornithine; Formycins; Inosine; Mice; | 1987 |
Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.
Topics: Administration, Oral; Adolescent; Adult; Animals; Child; Eflornithine; Female; Humans; Injections, I | 1987 |
Chemotherapy of trypanosomiasis: the use of guanylhydrazone compounds in the treatment of experimental murine trypanosomiasis.
Topics: Animals; Drug Therapy, Combination; Eflornithine; Female; Mice; Mitoguazone; Suramin; Trypanocidal A | 1987 |
African sleeping sickness in the United States. Successful treatment with eflornithine.
Topics: Animals; California; Child, Preschool; Congo; Democratic Republic of the Congo; Eflornithine; Female | 1988 |
Use of difluoromethylornithine (DFMO, eflornithine) for late-stage African trypanosomiasis.
Topics: Animals; Central Nervous System Diseases; Eflornithine; Humans; Mice; Trypanosomiasis, African | 1987 |
[African sleeping sickness].
Topics: Animals; Eflornithine; Humans; Trypanosoma brucei brucei; Trypanosoma brucei gambiense; Trypanosomia | 1988 |
Immune response to minor variant antigen types (VATs) in a mixed VAT infection of the African trypanosomes.
Topics: Animals; Antibodies, Protozoan; Antigenic Variation; Eflornithine; Immune Tolerance; Mice; Trypanoso | 1988 |
[Action of drugs tested in an acellular medium and in mice infected with Trypanosoma brucei brucei].
Topics: Acetanilides; Animals; Culture Media; Cyclosporins; Eflornithine; In Vitro Techniques; Melarsoprol; | 1988 |
[Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
Topics: Adult; Animals; Drug Administration Schedule; Eflornithine; Female; Humans; Male; Middle Aged; Trypa | 1988 |
[Arsenical resistance and difluoromethylornithine in the treatment of human African trypanosomiasis].
Topics: Arsenicals; Drug Resistance; Eflornithine; Humans; Melarsoprol; Trypanosomiasis, African | 1988 |
Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis.
Topics: Animals; Eflornithine; Kinetics; Male; Ornithine; Ornithine Decarboxylase Inhibitors; Putrescine; Ra | 1985 |
[African trypanosomiasis of icterohemorrhagic form].
Topics: Eflornithine; France; Male; Ornithine; Tanzania; Travel; Trypanocidal Agents; Trypanosomiasis, Afric | 1985 |